NYMC Faculty Publications
Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Secukinumab, an Anti IL17A Monoclonal Antibody, for Patients with Moderate-to-Severe Hidradenitis Suppurativa
Journal Title
The British Journal of Dermatology
First Page
609
Last Page
611
Document Type
Letter to the Editor
Publication Date
September 2019
Department
Dermatology
Abstract
Hidradenitis Suppurativa (HS) is a chronic inflammatory skin disease of the apocrine gland-rich intertriginous areas.(1) HS lesions have an elevated Th17 immune response, and it is often challenging to treat patients, with existing therapies having limited efficacy.(2,3) We sought to investigate the role of secukinumab, a human monoclonal antibody that inhibits Interleukin-17A, in HS treatment. This article is protected by copyright. All rights reserved.
Recommended Citation
Prussick, L., Rothstein, B., Joshipura, D., Saraiya, A., Turkowski, Y., Abdat, R., Alomran, A., Zancanaro, P., Kachuk, C., Dumont, N., Gottlieb, A., & Rosmarin, D. (2019). Open-label, Investigator-Initiated, Single Site Exploratory Trial Evaluating Secukinumab, an Anti IL17A Monoclonal Antibody, for Patients with Moderate-to-Severe Hidradenitis Suppurativa. The British Journal of Dermatology, 181 (3), 609-611. https://doi.org/10.1111/bjd.17822
